Phillips-Medisize Expands Clinical Manufacturing Capabilities to Serve Drug Delivery Device Market

Phillips-Medisize, a Molex company, announced expansion of its current Global Innovation and Development (GID) site in Struer, Denmark with a dedicated Manufacturing Development and Clinical build unit, which is scheduled to open in the second quarter of 2020.  As a recognized global leader, Phillips-Medisize provides a wide range of custom drug delivery devices, connected health solutions and end-to-end manufacturing services worldwide.  

The Phillips-Medisize manufacturing facility will be equipped to serve clients with agile set up for cleanroom assembly and molding (e.g. for clinical trials).  Approximately 500 m² of floor space from the existing 8400 m² building will be repurposed for the cleanroom.  The facility is designed to support late stage development of medium- and high-volume products and processes, under GMP and using state-of-the-art equipment.   

“This expansion accelerates the manufacture of innovative, compliant and best-in-class products while reducing time to market and lowering launch risk for drug delivery device customers,” said John Horgan, Vice President, Global Sales and Marketing of Phillips-Medisize.  “Furthermore, it strengthens our client focus in Scandinavia by complementing the activities of our existing GID in Struer and our newest GID in Copenhagen.”